Vanguard Asset Management
URGN icon

Vanguard Asset Management’s UroGen Pharma URGN Stock Holding History

Vanguard Asset Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$957K Hold
26,004
– – ﹤0.01% 1894
2026
Q1 		$468K Buy
+26,004
New +$521K ﹤0.01% 2124

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

Vanguard Asset Management's URGN Position: Q2 2026 in Review

Vanguard Asset Management held its UroGen Pharma (URGN) position steady in Q2 2026 at 26,004 shares worth $957K. The position accounts for ﹤0.01% of the portfolio, ranked #1894.

Vanguard Asset Management first reported a position in URGN in Q1 2026 and has held it in 2 quarters since. 174 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Vanguard Asset Management held 26,004 shares of UroGen Pharma worth $957K as of Q2 2026.
  • Vanguard Asset Management left its UroGen Pharma share count unchanged in Q2 2026.
  • UroGen Pharma made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #1894 holding.
  • Vanguard Asset Management first reported a position in UroGen Pharma in Q1 2026 and has held it in 2 quarters since.
  • 174 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.